India is considered the fourth largest pharmaceutical producer by volume and the thirteenth largest by value. At the same time, the country is also a major exporter of medicines and a large supplier worldwide, where its generic production is transported widely and accounts for 20 to 22% of global production (Atusko and Takahiro, 2011). As a member of the WTO, India has amended the National Patent Law, 1970, known as the Weak Patent Protection Policy, in order to comply with and meet the requirements of Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 2005. Say no to plagiarism. Get a tailor-made essay on "Why Violent Video Games Shouldn't Be Banned"? Get Original Essay India introduced a new patent regime, which transformed the process patent into a product patent and increased the patent term from seven years to twenty. end of the year (Atusko & Takahiro, 2011). This new trend has brought enormous positive effects rather than negative effects that many companies had assumed before the new patent law came into force. The new patent law promulgated by the Government of India has had considerably positive effects on the pharmaceutical sector, including improving the sales, value and profits of the pharmaceutical industry, paving the way for increased investment in research and development and business expansion of pharmaceutical outsourcing. , patent law allows large Indian pharmaceutical companies to produce larger quantity and quality of products and earn more profits from their monopolistic market due to the protection of patent law and policy. For example, Ranbaxy Laboratories Ltd is a famous Indian pharmaceutical company that ranks among the top ten international pharmaceutical companies and operates in around 49 countries across the world (ASA & Associates LPP, 2015). In compliance with the TRIPS agreement and adopting the new patent protection policy of the Government of India, Ranbaxy has acquired quite large positive gains in the TRIPS period. Ranbaxy's net worth has grown dramatically from $204.8 million in 1995 to $523.8 million in 2016. And the company's sales growth was 16.2 in the years from 1995 to 2000 and has been increasing rapidly by 104 in the period between 2000 and 2006. Furthermore, the value The sales ratio of the company ranked first by increase from 252.7 in 1995 to 933.9 in 2006. The profitability ratio also in the period it increased steadily from 10.2 in the period between 1995 and 2000 to 11.7 in the period between 2000 and 2006. Last but not least, the ratio of exports to total sales turnover of Ranbaxy was only 38, 4% in 1995, but the number continued to increase to 65.8% in 2006 (Biswajit and Gopakumar). Second, it pushes for high spending and greater investment in research and development in the pharmaceutical sector. Due to the strengthening of patent protection, many manufacturers and pharmaceutical companies have paid close attention and made huge investments in research and development to develop new drugs and new technologies so that they can maintain a competitive position in the global market. Based on CMIE statistical data it was found that the amount of expenditure on Indian pharmaceutical research and development increased substantially from Rs 35.01 core to Rs 471.38 core in 2010 (India's New Product Patent Regime, 2012). The pharmaceutical industry has focused on three main aspects of research and development, including new drug delivery systems (NDDS), research and development for the regulated market and non-infringement processes, and new drug development research (NDDR ), 2011).